Hokkaido Drug Wholesaler Hamada Files Bankruptcy
This article was originally published in PharmAsia News
Executive SummarySapporo based drug wholesaler Hamada filed for bankruptcy protection Feb. 9. According to Teikoku Databank, Hamad had ¥500 million in debt. Established in October 1952, Hamada handles a wide range of products from testing agents to vaccines. At its peak in March 2003, the company achieved ¥880 million in sales. However, with recent governmental budget cuts and reductions in subsidiaries, the company's sales dropped to ¥730 million in March 2008. Creditors have until March 13 to file a claim and the first creditor's meeting is scheduled May 14. (Click here for more - Japanese language
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.